EudraCT number: 2005-000629-32
Sponsor: University of Oxford
A multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer.
QUASAR 2 is a study comparing 'standard' chemotherapy using capecitabine, against capecitabine + Avastin® (bevacizumab) with the expectation that adding bevacizumab to capecitabine may have the potential for improved relapse free and overall survival compared to capecitabine alone.
Summary of Results: